TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03792906
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic norepinephrine infusion will be started after subarachnoid block.
Study: NCT02874989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01967329
Drug: Standard Triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)
Study: NCT01967329
Drug: Sequential
Normalized name: TABLET, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
Study: NCT01155518
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intramuscular every 2 weeks
Study: NCT01155518
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular saline injections every 2 weeks
Study: NCT01155518
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02566369
Drug: CD5789 (trifarotene) 50μg/g cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.
Study: NCT02566369
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied once daily for 12 weeks
Study: NCT00742261
Drug: GSK1363089
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
Study: NCT00984646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
Study: NCT04347174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician
Study: NCT01754805
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT04551534
Drug: DNL201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose(s)
Study: NCT04551534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose(s)
Study: NCT03358524
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar capsule manufactured to mimic vitamin E capsule once per day
Study: NCT02296645
Drug: ZuraPrep
Normalized name: DuraPrep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply topically.
Study: NCT00593190
Drug: Gas SF6 (Sulfur Hexafluoride)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONCE
Study: NCT04578236
Drug: Drug: Standard treatment Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Standard treatment Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study: NCT00859313
Drug: Sufentanil NanoTab PCA System/15 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
Study: NCT00212368
Drug: Zinc acetate
Normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01551511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical step-up approach to the Namisol arm.
Study: NCT01995188
Drug: DNIB0600A
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNIB0600A at an initial dose of 1.2 mg/kg will be administered via IV infusion further following a dose-escalation until DLT under consultation of the investigator on Day 1 of 21 day dose-escalation cycle. RP2D will be administered further in dose-expansion for until disease progression or death, whichever occurs first.
Study: NCT01072604
Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One oral dose of new formula Aspirin Prototype 1 under fasting conditions
Study: NCT01072604
Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One oral dose of new formula Aspirin Prototype 2 under fasting conditions
Study: NCT01072604
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One oral dose of Aspirin Plain Tablet under fasting conditions
Study: NCT01072604
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One oral dose of Aspirin Dry Granules under fasting conditions
Study: NCT03417154
Drug: Low dose Cyclophosphamide (CTX) Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide 50mg + nivolumab 3 mg/kg IV every 2 weeks for up to 4 courses of treatment
Study: NCT03417154
Drug: Low dose Cyclophosphamide (CTX) Every 7 Days
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral cyclophosphamide 350 mg every 7 days + nivolumab 3mg/kg IV every 2 weeks for up to 4 courses of treatment
Study: NCT00212589
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00212589
Drug: Fluorouracil + folinic acid
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00958516
Drug: LEO 29102 cream
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEO 29102 cream in different doses and the cream vehicle
Study: NCT00135499
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m², D1, 4 cycles
Study: NCT00135499
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg/m², D1, 4 cycles
Study: NCT00135499
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m², D1, 4 cycles
Study: NCT00135499
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m², D1, 4 cycles
Study: NCT03836261
Drug: Chemoimmunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)
Study: NCT04200352
Drug: TEV-50717
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets are 6, 9, and 12 mg.
Study: NCT04371393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day)
Study: NCT02162199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.
Study: NCT00452972
Drug: Spinal Anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03818334
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 1000 mg/flask
Study: NCT04179929
Drug: Pediatric-type of chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric type chemotherapy (induction, early and delayed consolidation, reinduction, maintenance). Induction (VCR,PDN,PegASP,DNR). Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP). Reinduction (VCR, PDN, PegASP, DNR). Maintenance (Methotrexate, Mercaptopurine)
Study: NCT00673712
Drug: Opioid based analgesia
Normalized name: OPIOID ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid Analgesic agents delivered by:~PCA on demand mode IV injections PRN IM injections PRN Oral PRN
Study: NCT00743873
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of 6 cc of saline into injured area
Study: NCT04217941
Drug: Health Education and practical demonstration of Nasal spray and intranasal ointment
Normalized name: betamethasone / gentamicin Topical Spray [Betagen brand of Betamethasone and Gentamicin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: We compared the effect of Health education and practical demonstration for using nasal spray and apply intranasal ointment compared to health education without practical demonstration
Study: NCT04421027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00065572
Drug: ZD6126
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00065572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00590772
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 2 weeks
Study: NCT02560545
Drug: Cannabis oil
Normalized name: Cannabis oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis oil 20% THC
Study: NCT01460043
Drug: Homeopathy
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each homeopathic medication was given as 1 g dose of homeopathic preparation in 30c potency. The dose is prepared as lactose globules on which the homeopathic preparation.
Study: NCT01460043
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: corresponding placebo was identical in appearance of homeopathic globule prepared in alcohol.
Study: NCT00036868
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00036868
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00036868
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00337623
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02461407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo p.o. qd
Study: NCT02873702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole placebo-matching capsules.
Study: NCT01977482
Drug: GSK1278863
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
Study: NCT01977482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet for GSK1278863
Study: NCT04743986
Drug: Corticosteroid (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg/ml triamcinolone in 2 ml 0.5% bupivicaine
Study: NCT01851603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical diluent to that used for AVL-3288
Study: NCT01650597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
Study: NCT00114517
Drug: 17B-estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 17B-estradiol 1 mg daily
Study: NCT03252925
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg/Kg.d, oral
Study: NCT04396236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00967421
Drug: ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BAC level 0.5 g/dL (drink + placebo pill). Drink with 2,4 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
Study: NCT00967421
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BAC level 1.0 g/dL (drink + placebo pill). Drink with 3,6 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
Study: NCT04320589
Drug: General anesthetic
Normalized name: General anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1) Traditional group in which the patients̕ hemodynamic adjustment will be conducted using orally or IV α₁ \& β-adrenergic blockers \[Prazocin (minipress): 0.5-20 mg/day, Propranolol (Inderal) :10-360 mg/day, Bisoprolol (Concor): 2.5-20 mg/day, Atenolol (Tenormin): 25-100 mg/day \&/or Labetalol (Trandate)200-600 mg/day, ACI \& ACRB e.g. Tritace 2.5-10 mg/day \& Atacand 4-16 mg/day\]
Study: NCT02563067
Drug: QAW039
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAW039 150 mg once daily
Study: NCT02563067
Drug: QAW039
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAW039 450 mg once daily
Study: NCT02563067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT00839319
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg testosterone gel applied transdermally for 10 days
Study: NCT04323657
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Flu/Cy Lymphodepletion
Study: NCT00938275
Drug: 0.5g SRT2104
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 will be supplied in two forms: as 0.5g powder which will be prepared by the pharmacist/designee into a liquid suspension and as two hard gelatin capsules, each containing 0.25g SRT2104. The dosing vehicle for the liquid suspension is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104.~Each formulation of test material will be administered orally, in a single dose to the subjects in the fasted state and following consumption of a standard meal. Neither the investigator nor the subjects enrolled will be blinded to treatment assignment.
Study: NCT02892916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A bolus of an intravenous normal saline solution following induction of anaesthesia.
Study: NCT01847326
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01416324
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle used to dilute the powder for oral administration.
Study: NCT01416324
Drug: 0.1 mg GSK2330672
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Study: NCT01416324
Drug: 0.3 mg GSK2330672
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Study: NCT01416324
Drug: 1 mg GSK2330672
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Study: NCT01416324
Drug: 3 mg GSK2330672
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Study: NCT01416324
Drug: 10 mg GSK2330672
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Study: NCT01416324
Drug: 30 mg GSK2330672
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Study: NCT01416324
Drug: 60 mg GSK2330672
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
Study: NCT00955916
Drug: CLAG Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The CLAG regimen consisted of: Cladribine, 5 mg/m\^2 administered via 2 hour IV daily for 5 consecutive days starting on day 2; Cytarabine, 2 mg/m\^2 administered through a 4 hour IV starting 2 hours after the ignition of Cladribine for 5 days starting on day 2; granulocyte colony-stimulating factor (G-CSF): 300 mcg subcutaneous (SC) for 6 days starting 12-24 hours (Day 1) before the first dose of Cladribine.
Study: NCT00955916
Drug: Gleevec®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib mesylate 400 mg orally twice daily was administered on day 2 to day 15. Re-induction was allowed if participant had partial response (PR).
Study: NCT03257319
Drug: IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient in arm A will receive 1 to 6 injection
Study: NCT00004669
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03925779
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil sedation
Study: NCT01041755
Drug: L-ornithine-L-aspartate
Normalized name: ornithine, (L)-isomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: a) Intravenous infusion of 20 g L-ornithine-L-aspartate (4 ampules of 10 mL each) in 250 mL sodium chloride solution administered daily in 4 hours for 3 consecutive days, plus the placebo b) Water enemas, 1000 mL of water and given as retention enema every 12 hours for 3 consecutive days.
Study: NCT01041755
Drug: Lactose
Normalized name: Lactose
DrugBank: Lactose (DB04465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a) 20% Lactose enemas, 200 g Lactose diluted with 700 mL of water and given as retention enema every 12 hours for 3 consecutive days, plus intravenous placebo b)250 mL sodium chloride solution, infusion for 4 hours for 3 consecutive days.
Study: NCT04468997
Drug: Drug 601
Normalized name: ethanol 0.601 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.375mg), Vitreous injection, injection once;
Study: NCT04468997
Drug: Drug 601
Normalized name: ethanol 0.601 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(0.75mg), Vitreous injection, injection once;
Study: NCT04468997
Drug: Drug 601
Normalized name: ethanol 0.601 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once;
Study: NCT04468997
Drug: Drug 601
Normalized name: ethanol 0.601 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once;
Study: NCT04468997
Drug: Drug 601
Normalized name: ethanol 0.601 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(1.25mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.
Study: NCT04468997
Drug: Drug 601
Normalized name: ethanol 0.601 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant humanized anti-VEGF monoclonal antibody, drug 601(2.5mg), Vitreous injection, injection once every 4 weeks, three times continuously, then injection as needed within 9 months.
Study: NCT00862667
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00241939 300ug using Inhaler B
Study: NCT03841630
Drug: LY3437943
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (SC)
Study: NCT03841630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03455842
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week
Study: NCT01668862
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
Study: NCT01423747
Drug: VP16, ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
Study: NCT01423747
Drug: VP16, ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
Study: NCT01851759
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.
Study: NCT01716442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03198507
Drug: RHB-105
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of:~* Rifabutin 150 mg~* Amoxicillin 3000 mg~* Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind.
Study: NCT00343460
Drug: APF530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given subcutanously
Study: NCT03805152
Drug: Neuronox(R)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection botulinum toxin intramuscular for affected neck muscle
Study: NCT03292796
Drug: Prostaglandins
Normalized name: PROSTAGLANDINS
DrugBank: Prostaglandin G2 (DB03866)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00700115
Drug: Pre-study antiretroviral regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of pre-study antiretroviral regimen
Study: NCT01666041
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006340
Drug: arginine butyrate
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no